Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10171
Title: Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Authors: Lee, Oi Lin
Horvath, Noemi
Lee, Cindy
Joshua, Doug
Ho, Joy
Szer, Jeff
Quach, Hang
Spencer, Andrew
Harrison, Simon
Mollee, Peter
Roberts, Andrew W
Talaulikar, Dipti
Brown, Ross
Augustson, Bradley
Ling, Silvia
Jaksic, Wilfrid
Gibson, John
Kalff, Anna
Johnston, Anna
Kalro, Akash
Ward, Chris
Prince, H Miles
Zannettino, Andrew
Affiliation: Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia..
Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Department of Cancer and Haematology, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Department of Cancer and Haematology, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.. School of Medicine, University of Queensland, Brisbane, Queensland, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia.. Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.. College of Medicine, Biology and Environment, Australian National University, Canberra, Australian Capital Territory, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Liverpool Hospital, Sydney, New South Wales, Australia.. South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Department of Cancer and Haematology, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.. Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Cancer and Haematology, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Department of Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia..
Issue Date: Aug-2017
Citation: Internal medicine journal 2017-08; 47(8): 938-951
Abstract: Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal-related events such as pathologic fracture, spinal cord compression and hypercalcaemia. MBD is the result of MM plasma cells-mediated activation of osteoclast activity and suppression of osteoblast activity. Bisphosphonates (BP), pyrophosphate analogues with high bone affinity, are the only pharmacological agents currently recommended for the treatment and prevention of MBD and remain the standard of care. Pamidronate and zoledronic acid are the most commonly used BP to treat MBD. Although generally safe, frequent high doses of BP are associated with adverse events such as renal toxicity and osteonecrosis of the jaw. As such, optimal duration and dosing of BP therapy is required in order to minimise BP-associated adverse events. The following guidelines provide currently available evidence for the adoption of a tailored approach when using BP for the management of MBD.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10171
DOI: 10.1111/imj.13502
ORCID: http://orcid.org/0000-0001-6783-2301
http://orcid.org/0000-0002-6646-6167
Type: Journal Article
Subjects: bisphosphonate
myeloma
osteoblast
osteoclast
osteolysis
skeletal-related event (SRE)
Bisphosphonate-Associated Osteonecrosis of the Jaw
Bone Density Conservation Agents
Bone Neoplasms
Bone and Bones
Diphosphonates
Evidence-Based Medicine
Humans
Kidney Diseases
Multiple Myeloma
Radiography
Risk Factors
Practice Guidelines as Topic
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.